Study identifier:D1843R00323
ClinicalTrials.gov identifier:NCT04709263
EudraCT identifier:N/A
CTIS identifier:N/A
Heart Failure patients registry A prospective observational multicenter registry of patients with chronic heart failure in the population of the Russian Federation (PRIORITY-HF)
heart failure
N/A
No
-
All
20514
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
-
This study is a multicenter non-interventional observational prospective registry. This non-interventional study (NIS) does not imply any intervention into a routine clinical practice, including choice of treatment modality or special methods of investigation. The study will include only those patients who sign the informed consent form (ICF) after explanation of the study objectives and methods by the study physician. Planned study population consists of 20 000 adult outpatients with HF. All patients with HF who signed an ICF will be included to this study. Planned number of study sites is 150 outpatient centers in about 50 regions (in order to describe characteristics of outpatients with HF in different regions in the most comprehensive way). Expected inclusion period duration – 24 months OR reaching 20 000 patients, if this takes less than 24 months. Planned follow-up period duration for 1 patient is about 52 weeks (12 months), which includes 3 visits (visit 1 – inclusion; visit 2 – approximately 6 months after inclusion; visit 3 – approximately 12 months after inclusion)
Location
Location
Krasnodar, Russian Federation
Location
Ekaterinburg, Russian Federation
Location
Moscow, Russian Federation
Location
Voronezh, Russian Federation
Location
Lipetsk, Russian Federation
Location
Kursk, Russian Federation
Location
Belgorod, Russian Federation
Location
Stary Oskol, Belgorod region, Russian Federation
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.